AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23535809 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral liquid (CON)
Number of subjects: 10
Study 23535809 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral liquid consumption with expectorated ice slushy mouthwash (WASH)
Number of subjects: 10
Study 21157047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12%
Number of subjects: 40
Study 21157047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.06%
Number of subjects: 40
Study 21157047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.02%
Number of subjects: 40
Study 21157047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 40
Study 18849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg per day for 5 days, then reduced by 10 mg per day for a total of 10 days)
Number of subjects: 829
Study 18849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (1000 mg three times per day for 7 days)
Number of subjects: 829
Study 18849193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 18849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus valaciclovir
Number of subjects: 829
Study 18849193 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 829
Study 15914049 — intervention group
Group type: EXPERIMENTAL
Intervention: Durogesic fentanyl transdermal reservoir (TDF)
Number of subjects: 680
Study 15914049 — intervention group
Group type: COMPARATOR
Intervention: Oral sustained-release morphine (SRM)
Number of subjects: 680
Study 12806323 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative endodontic access
Number of subjects: 90
Study 12806323 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of all cusps
Number of subjects: 90
Study 12806323 — intervention group
Group type: COMPARATOR
Intervention: Other groups (7 groups with varying degrees of tooth loss)
Number of subjects: 90
Study 11106307 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg i.v.)
Number of subjects: 16
Study 11106307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8657447 — intervention group
Group type: EXPERIMENTAL
Intervention: Zantac (histamine H2-receptor antagonist)
Number of subjects: 64
Study 1310921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 10 micrograms min‐1 kg‐1
Number of subjects: 8
Study 1310921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 8
Study 1310921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 2 and 5 micrograms min‐1 kg‐1
Number of subjects: 8
Study 6432353 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF (adriamycin, cyclophosphamide, ftorafur)
Number of subjects: 60
Study 6432353 — intervention group
Group type: COMPARATOR
Intervention: ACFM (adriamycin, cyclophosphamide, ftorafur, methotrexate)
Number of subjects: 60
Study 6432353 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF
Number of subjects: 60
Study 6432353 — intervention group
Group type: COMPARATOR
Intervention: ACFM
Number of subjects: 60
Study 30627737 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 50 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M1)
Number of subjects: 90
Study 30627737 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 100 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M2)
Number of subjects: 90
Study 30627737 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2% and hyaluronidase 15 IU/ml (Group C)
Number of subjects: 90
Study 29469951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam as an adjuvant to haloperidol
Number of subjects: 90
Study 29469951 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an adjuvant to haloperidol
Number of subjects: 90
Study 27655031 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber meal
Number of subjects: 20
Study 27655031 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber meal
Number of subjects: 20
Study 24519039 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon‐α2a and 800 mg daily dose of ribavirin
Number of subjects: 354
Study 24519039 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPA gene variants predicting reduced ITPase activity
Number of subjects: 354
Study 24519039 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for both major alleles (normal ITPase activity)
Number of subjects: 354
Study 23023457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog bite prevention report (PAR‐DB)
Number of subjects: 901
Study 23023457 — intervention group
Group type: COMPARATOR
Intervention: Other safety behaviors report (PAR‐S)
Number of subjects: 901
Study 20202351 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing
Number of subjects: 0
Study 20202351 — intervention group
Group type: COMPARATOR
Intervention: Pathology laboratory testing
Number of subjects: 0
Study 17541262 — intervention group
Group type: EXPERIMENTAL
Intervention: Respironics REMstar Auto (RR)
Number of subjects: 50
Study 17541262 — intervention group
Group type: COMPARATOR
Intervention: ResMed Spirit (RS)
Number of subjects: 50
Study 15673895 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg)
Number of subjects: 0
Study 15673895 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine (7.5 mg)
Number of subjects: 0
Study 12559222 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203
Study 12559222 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study 10577621 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diathermy
Number of subjects: 222
Study 10577621 — intervention group
Group type: COMPARATOR
Intervention: Laser conization
Number of subjects: 222
Study 8314652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of E2020 (0.3 mg, 1 mg, 2 mg, 5 mg, 8 mg, 10 mg) in fasting condition
Number of subjects: 0
Study 8314652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of E2020 (2 mg) after a meal
Number of subjects: 0
Study 8314652 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral doses of E2020 (2 mg once daily for 21 days)
Number of subjects: 0
Study 8314652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of E2020 (10 mg)
Number of subjects: 0
Study 3034017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 86
Study 3034017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg once daily
Number of subjects: 86
Study 3034017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29800767 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame induction
Number of subjects: 141
Study 29800767 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt induction
Number of subjects: 141
Study 29800767 — intervention group
Group type: COMPARATOR
Intervention: Neutral induction
Number of subjects: 141
Study 27665708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing for 1 minute after seated SBP measurements
Number of subjects: 8662
Study 27665708 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with changes in BP upon standing
Number of subjects: 8662
Study 25959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily for six weeks
Number of subjects: 23
Study 25959271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23848435 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite acute exacerbation
Number of subjects: 35
Study 23848435 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected acute exacerbation
Number of subjects: 35
Study 23848435 — intervention group
Group type: EXPERIMENTAL
Intervention: Other
Number of subjects: 35
Study 23848435 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite and suspected acute exacerbations
Number of subjects: 35
Study 23848435 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory serious adverse events
Number of subjects: 35
Study 20850327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring (HT) autografts
Number of subjects: 1643
Study 20850327 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) autografts
Number of subjects: 1643
Study 20850327 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-strand HT combined with modern endobutton HT graft-fixation technique
Number of subjects: 1643
Study 20850327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HT and BPTB autografts
Number of subjects: 1643
Study 19567528 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone low dose (T-LD) 0.75 mg/12 h iv
Number of subjects: 14
Study 19567528 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone high dose (T-HD) 2.5 mg/12 h iv
Number of subjects: 14
Study 19567528 — intervention group
Group type: COMPARATOR
Intervention: Saline (baseline)
Number of subjects: 14
Study 16919138 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 11
Study 16919138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16279280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 0
Study 16279280 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 11775648 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG) applied locally for 2 weeks
Number of subjects: 35
Study 11775648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35
Study 9534493 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for measurement of shoulder movements using the Plurimeter-V inclinometer
Number of subjects: 6
Study 7746029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretazenil 0.25 mg
Number of subjects: 12
Study 7746029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretazenil 0.5 mg
Number of subjects: 12
Study 7746029 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 12
Study 7746029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2728956 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped training program on resisting pressures to smoke
Number of subjects: 0
Study 2728956 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 30084098 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of honey on oral mucosa
Number of subjects: 100
Study 30084098 — intervention group
Group type: COMPARATOR
Intervention: Routine practice of analgesic and antiseptic gel application (Control)
Number of subjects: 100
Study 28615010 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training.
Number of subjects: 0
Study 28615010 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 26147236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART), a 12‐session, manualized compensatory cognitive training intervention
Number of subjects: 50
Study 26147236 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment combined with compensatory cognitive training (CogSMART)
Number of subjects: 50
Study 26147236 — intervention group
Group type: COMPARATOR
Intervention: Supported employment only
Number of subjects: 50
Study 24592578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 34
Study 21664068 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 212
Study 21664068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 212
Study 21664068 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 212
Study 18622361 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 20
Study 18622361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 20
Study 18622361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17069545 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 24
Study 17069545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12688593 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer on day 1
Number of subjects: 329
Study 12688593 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer on days 2 and 3
Number of subjects: 329
Study 12688593 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on days 4 and 5
Number of subjects: 329
Study 10737166 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 44
Study 10737166 — intervention group
Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 44
Study 9186317 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg OTZ
Number of subjects: 12
Study 9186317 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/kg OTZ
Number of subjects: 12
Study 9186317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8383319 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryltrinitrate (GTN) ointment
Number of subjects: 40
Study 8383319 — intervention group
Group type: COMPARATOR
Intervention: Heparinoid ointment (Control)
Number of subjects: 40
Study 3022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 1.5 mg/kg
Number of subjects: 18
Study 3022628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 18
Study 3022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) and Placebo
Number of subjects: 18
Study 30374129 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus
Number of subjects: 0
Study 27171324 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (9 puffs for up to 15 kg, 12 puffs for >15-20 kg, 15 puffs for >20-25 kg, 18 puffs for >25 kg)
Number of subjects: 119
Study 27171324 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 puffs for up to 25 kg, 12 puffs for >25 kg)
Number of subjects: 119
Study 27171324 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (various dosages as per weight)
Number of subjects: 119
Study 23328180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of mitomycin-C (0.4 mg/ml) adjuncted with interventional bronchoscopy
Number of subjects: 20
Study 23328180 — intervention group
Group type: COMPARATOR
Intervention: Interventional bronchoscopy only (control group)
Number of subjects: 20
Study 20191257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber group (oat-bran 5.2g/d for 84 days)
Number of subjects: 30
Study 20191257 — intervention group
Group type: COMPARATOR
Intervention: Control group (ward's habitual diet)
Number of subjects: 30
Study 20191257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber group
Number of subjects: 30
Study 20191257 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 18360047 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 100
Study 18360047 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 100
Study 15951472 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated microgravity (smuG)
Number of subjects: 6
Study 15951472 — intervention group
Group type: COMPARATOR
Intervention: Normal gravity (1G)
Number of subjects: 6
Study 12638278 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 16
Study 11563410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered 10 minutes before a high-fat breakfast meal
Number of subjects: 12
Study 11563410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered immediately after a high-fat breakfast meal
Number of subjects: 12
Study 11563410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg and 60 mg under fasting conditions
Number of subjects: 12
Study 11563410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide taken prior to the meal
Number of subjects: 12
Study 8955514 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged men
Number of subjects: 2
Study 8955514 — intervention group
Group type: COMPARATOR
Intervention: Young men
Number of subjects: 2
Study 8955514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 2
Study 1819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.16 g per day for 4 weeks
Number of subjects: 12
Study 1819709 — intervention group
Group type: COMPARATOR
Intervention: Olive oil 12 g per day for 4 weeks
Number of subjects: 12
Study 7288877 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral contracting (with or without family involvement) and weekly telephone contacts
Number of subjects: 116
Study 7288877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 30160369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard postoperative G‐tube care
Number of subjects: 171
Study 30160369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid G‐tube dressing
Number of subjects: 171
Study 30160369 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver‐impregnated hydrocolloid G‐tube dressing
Number of subjects: 171
Study 30160369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed hypergranulation tissue
Number of subjects: 171
Study 30160369 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not develop hypergranulation tissue
Number of subjects: 171
Study 27756804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) and adjunctive intra-arterial mechanical thrombectomy (MT)
Number of subjects: 65
Study 26542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional rehabilitation program (8 weeks, 3 days per week, 30-min sessions)
Number of subjects: 40
Study 26542104 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education program (once a month over 8 weeks)
Number of subjects: 40
Study 26542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional rehabilitation program
Number of subjects: 40
Study 23535007 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen continued for a week
Number of subjects: 80
Study 23535007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dexamethasone
Number of subjects: 80
Study 23535007 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen continued for a week + Intraoperative dexamethasone
Number of subjects: 80
Study 23535007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21112746 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 25mg bid
Number of subjects: 40
Study 21112746 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20mg uid
Number of subjects: 40
Study 19734682 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus gasseri OLL2809 (100 mg per day for 8 weeks)
Number of subjects: 0
Study 19734682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16770979 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention group
Number of subjects: 1446
Study 16770979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1446
Study 15867741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppository
Number of subjects: 0
Study 15867741 — intervention group
Group type: COMPARATOR
Intervention: Usual ostomy emptying practice
Number of subjects: 0
Study 11275800 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied to the ulcer for 30-45 minutes under occlusion
Number of subjects: 0
Study 11275800 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study 9428981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 0.1 mg/kg x d
Number of subjects: 128
Study 9428981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 0.05 mg/kg x d
Number of subjects: 128
Study 9428981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 8275193 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol, beta-carotene, and vitamin E
Number of subjects: 532
Study 8275193 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (medium blood concentration)
Number of subjects: 532
Study 8275193 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (high blood concentration)
Number of subjects: 532
Study 8275193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (high blood concentration)
Number of subjects: 532
Study 3755517 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplement of 1000 IU/day during the last three months of pregnancy
Number of subjects: 77
Study 3755517 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 5 mg at the seventh month of pregnancy
Number of subjects: 77
Study 3755517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 77
Study 31243706 — intervention group
Group type: EXPERIMENTAL
Intervention: Time series regressions using lagged inputs after treatment initiation
Number of subjects: 3657
Study 31243706 — intervention group
Group type: COMPARATOR
Intervention: Baseline data only
Number of subjects: 3657
Study 31243706 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient distributions for >50% pain score improvements
Number of subjects: 3657
Study 29726344 — intervention group
Group type: COMPARATOR
Intervention: 10 Hz rTMS
Number of subjects: 414
Study 29726344 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 414
Study 27097389 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarette smokers (group 1)
Number of subjects: 98
Study 27097389 — intervention group
Group type: COMPARATOR
Intervention: Non-electronic cigarette smokers (group 2)
Number of subjects: 98